Viking Therapeutics (VKTX) News Today $51.74 +0.21 (+0.41%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Viking Therapeutics (NASDAQ:VKTX) Shares Up 0.3% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Stock Price Up 0.3% - Here's What HappenedNovember 21 at 2:47 PM | marketbeat.comRoyce & Associates LP Invests $844,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)Royce & Associates LP acquired a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 13,334 shares of the biotechnology company's stock, vNovember 21 at 3:39 AM | marketbeat.comBrokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $109.80November 21 at 1:29 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.5% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Shares Down 0.5% - Here's WhyNovember 20 at 2:49 PM | marketbeat.comViking Therapeutics Garners Analyst Support For NASH And Metabolic ProgramsNovember 20 at 2:02 PM | benzinga.comViking Therapeutics is more than just a weight-loss stock, and that’s drawing cheersNovember 20 at 12:12 PM | marketwatch.comViking Therapeutics (NASDAQ:VKTX) Earns Outperform Rating from William BlairWilliam Blair reaffirmed an "outperform" rating on shares of Viking Therapeutics in a research note on Wednesday.November 20 at 11:38 AM | marketbeat.comJW Asset Management LLC Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)JW Asset Management LLC purchased a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,000 shares of the biotechNovember 20 at 8:53 AM | marketbeat.comViking to present data from Phase 2b VOYAGE study in late breaker presentationNovember 20 at 1:40 AM | markets.businessinsider.comViking phase 2b study of NASH candidate hits primary endpointNovember 20 at 1:40 AM | msn.comViking Therapeutics reports results from Phase 2b clinical trial of VK2809November 20 at 1:40 AM | markets.businessinsider.comViking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024November 19 at 4:03 PM | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Trading Down 1% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Trading Down 1% - Here's WhyNovember 19 at 3:52 PM | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXNovember 18 at 9:52 PM | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Shares Down 1.4% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Shares Down 1.4% - Time to Sell?November 18 at 3:22 PM | marketbeat.com3 Things You Need to Know if You Buy Viking Therapeutics TodayNovember 18 at 5:05 AM | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Buy" by BrokeragesShares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have earned an average rating of "Buy" from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and one has given a strong buy rNovember 18 at 1:31 AM | marketbeat.comIs It Too Late to Buy Viking Therapeutics Stock?November 17, 2024 | fool.comLJI Wealth Management LLC Has $1.17 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)LJI Wealth Management LLC lessened its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 39.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 18,400 shares of the biotechnology company's stock after selling 11,800 shares during thNovember 16, 2024 | marketbeat.comPrediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.November 16, 2024 | fool.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.9% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 2.9% - What's Next?November 15, 2024 | marketbeat.comShould You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?November 15, 2024 | yahoo.comOppenheimer & Co. Inc. Buys 31,011 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Oppenheimer & Co. Inc. increased its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 43.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 102,324 shares of the biotechnology company's stock after acquiring an additionalNovember 15, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 1% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 1% - Time to Sell?November 14, 2024 | marketbeat.comAptus Capital Advisors LLC Boosts Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Aptus Capital Advisors LLC lifted its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 34.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,143 shares of the biotechnology company's stocNovember 14, 2024 | marketbeat.comSigma Planning Corp Takes $957,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Sigma Planning Corp bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 15,119 shares of the biotechnology company's stock, valued at approximately $957,000. ANovember 14, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 3.1% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Shares Down 3.1% - Should You Sell?November 13, 2024 | marketbeat.comDid Viking Therapeutics Just Say "Checkmate" To Eli Lilly?November 13, 2024 | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Chartwell Investment Partners LLCChartwell Investment Partners LLC lifted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 88.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,666 shares of the biotechnology company's stock aNovember 13, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 5.6% - What's Next?Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.6% - Here's What HappenedNovember 12, 2024 | marketbeat.comViking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024November 12, 2024 | prnewswire.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. boosted its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 29.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 593,528 shares of the biotechnology coNovember 12, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 2.2% After Insider SellingViking Therapeutics (NASDAQ:VKTX) Stock Price Down 2.2% on Insider SellingNovember 11, 2024 | marketbeat.comIs Viking Therapeutics a Buy on the Dip?November 10, 2024 | fool.comLawson Macartney Sells 2,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) StockNovember 9, 2024 | insidertrades.comFiera Capital Corp Makes New $18.44 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Fiera Capital Corp acquired a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 291,318 shares of the biotechnology company'sNovember 9, 2024 | marketbeat.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Sells 2,000 Shares of StockViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) Director Lawson Macartney sold 2,000 shares of the business's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $68.67, for a total transaction of $137,340.00. Following the completion of the sale, the director now owns 47,965 shares of the company's stock, valued at approximately $3,293,756.55. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.November 8, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.8% - What's Next?Viking Therapeutics (NASDAQ:VKTX) Trading Down 0.8% - Here's What HappenedNovember 8, 2024 | marketbeat.comHealthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZenecaNovember 8, 2024 | cnbc.comQuantum Private Wealth LLC Acquires 7,161 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Quantum Private Wealth LLC increased its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 9.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 84,084 shares of the biotechnology company's stock afterNovember 8, 2024 | marketbeat.com4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart MoveNovember 8, 2024 | fool.comViking Therapeutics (NASDAQ:VKTX) Shares Up 0.3% - Time to Buy?Viking Therapeutics (NASDAQ:VKTX) Trading Up 0.3% - Should You Buy?November 7, 2024 | marketbeat.comGot $5,000? Viking Therapeutics Stock Just Got a Big New Green FlagNovember 7, 2024 | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by AlphaCentric Advisors LLCAlphaCentric Advisors LLC decreased its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 78.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,500 shares of the biotechnology companyNovember 5, 2024 | marketbeat.comIs Viking Therepautics a Buy Now?November 5, 2024 | fool.comViking Therapeutics Stock Soars, Picks Up Retail Buzz On ‘Promising’ Early Results For Obesity PillNovember 5, 2024 | msn.comViking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And SafetyNovember 4, 2024 | finance.yahoo.comWhy Viking Therapeutics Stock Plummeted After Soaring TodayNovember 4, 2024 | fool.comHow does Viking's weight loss med compare to ones from Novo, Eli Lilly?November 4, 2024 | msn.comViking Therapeutics (VKTX) Gets a Buy from Stifel NicolausNovember 4, 2024 | markets.businessinsider.com Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now VKTX Media Mentions By Week VKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼0.490.48▲Average Medical News Sentiment VKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼2514▲VKTX Articles Average Week Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Today Puma Biotechnology News Today Marinus Pharmaceuticals News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Moderna News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.